Hony-Esneux, Belgium

Joel Pincemail


Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 34(Granted Patents)


Company Filing History:


Years Active: 1995-1999

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Joel Pincemail

Introduction

Joel Pincemail is a notable inventor based in Hony-Esneux, Belgium. He has made significant contributions to the field of biotechnology, particularly in the area of human myeloperoxidase. With a total of three patents to his name, Pincemail's work has implications for therapeutic applications.

Latest Patents

Pincemail's latest patents focus on human myeloperoxidase and its therapeutic applications. One of his patents describes a method for producing human myeloperoxidase by culturing prokaryotic or eukaryotic cells that have been transformed by a vector designed for the expression of this enzyme. Another patent outlines a method for preparing biologically active human myeloperoxidase, detailing the steps involved in creating a vector that includes plasmid pNIV2703. This plasmid features a cassette that contains a complete DNA sequence for human myeloperoxidase, which is crucial for its expression in CHO cells.

Career Highlights

Throughout his career, Pincemail has worked with esteemed institutions such as Université Libre de Bruxelles and La Région Wallonne. His research has contributed to advancements in the understanding and application of human myeloperoxidase, showcasing his expertise in the field.

Collaborations

Pincemail has collaborated with notable colleagues, including Carol Deby and Alex Bollen. These partnerships have further enriched his research and development efforts.

Conclusion

Joel Pincemail's innovative work in the field of biotechnology, particularly regarding human myeloperoxidase, highlights his significant contributions as an inventor. His patents and collaborations reflect a commitment to advancing therapeutic applications in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…